775302-21-1

Usage

Uses

Used in Pharmaceutical Research:
3-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]phenylamine is used as a building block for the development of potential therapeutic agents in the pharmaceutical industry. The presence of the 1,3,4-oxadiazole moiety, known for its pharmacological activities, makes it a valuable compound for creating new drugs with various applications.
Used in Organic Synthesis:
In the field of organic synthesis, 3-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]phenylamine is used as an intermediate for the synthesis of more complex molecules. Its unique structural features allow for further chemical reactions and modifications, leading to the creation of a wide range of compounds with different properties and applications.
Used in Material Science:
3-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]phenylamine also finds applications in material science, where its structural properties can be exploited to develop new materials with specific characteristics. 3-[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]phenylamine's aromatic amine and 1,3,4-oxadiazol-2-yl groups can contribute to the overall properties of the synthesized materials, making them suitable for various applications in different industries.

Upstream product

• 99-94-5 p-Toluic acid 
• 311313-24-3 N'-(4-methylbenzoyl)-3-nitrobenzohydrazide 
• 618-94-0 3-nitrobenzoic acid hydrazide 

Downstream Products

• 1620517-08-9 4-morpholino-N-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenyl)butanamide 
• 1620517-25-0 methyl 5-oxo-5-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenylamino)pentanoate 
• 1620516-94-0 5-hydroxy-N-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenyl)pentanamide 
• 1620517-30-7 C₁₉H₁₈ClN₃O₂ 
• 1620517-01-2 C₂₂H₂₃N₃O₄ 
• 1620517-23-8 N-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenyl)hex-5-enamide 
• 1620517-29-4 C₂₆H₃₁N₃O₄ 
• 1620517-28-3 C₂₅H₂₉N₃O₄ 
• 1620517-27-2 C₂₄H₂₇N₃O₄ 
• 1620517-26-1 C₂₃H₂₅N₃O₄ 
• 1620516-95-1 6-hydroxy-N-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenyl)hexanamide 
• 1620517-22-7 C₂₀H₁₉N₃O₄ 
• 1620517-21-6 C₁₉H₁₇N₃O₄ 
• 667434-78-8 N-(3-(5-p-tolyl-1,3,4-oxadiazol-2-yl)phenyl)pentanamide 

Relevant academic research and scientific papers

Synthesis and structure-activity relationship of non-phosphorus-based fructose-1,6-bisphosphatase inhibitors: 2,5-Diphenyl-1,3,4-oxadiazoles

With the aim of discovering a novel class of non-phosphorus-based fructose-1,6-bisphosphatase (FBPase) inhibitors, a series of 2,5-diphenyl-1,3,4-oxadiazoles were synthesized based on the hit compound (1) resulting from a high-throughput screening (HTS). Structure-activity relationship (SAR) studies led to the identification of several compounds with comparable inhibitory activities to AMP, the natural allosteric inhibitor of FBPase. Notably, compound 22 and 27b, bearing a terminal carboxyl or 1H-tetrazole, demonstrated remarkable inhibition to gluconeogenesis (GNG). In addition, both inhibition and binding mode to the enzyme were investigated by enzymatic kinetics and in silico experiments for representative compounds 16 and 22.

Design, synthesis and biological activity evaluation of 2,5-diphenyl-1,3,4-oxadiazole derivatives as novel inhibitors of fructose-1,6-bisphosphatase

Fructose-1,6-bisphosphatase (FBPase), an important gluconeogenic enzyme, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate. The effort to discover new FBPase inhibitors was carried out by high-throughput screening (HTS) of a library of 56,000 lead-like compounds, and a 2,5-diphenyl-1,3,4-oxadiazole (3a, IC50 = 15.45 μM) which bearing no phosphate group was identified as a potential FBPase inhibitor for the first time. Structure-activity-relationship (SAR) research of a series of analogues obtained by modifying the substituent groups and replacing the 1,3,4-oxadiazole with several other heterocycles disclosed the key structure and substituent groups related to the binding with FBPase.